Future Fields

Growth factors are signalling proteins that instruct cells to divide and differentiate, and they are indispensable to cell culture across research, therapeutics and cultivated meat. They are also the dominant cost in most of those processes. Produced conventionally in large stainless steel bioreactors, they demand capital equipment, sterile facilities and considerable energy, and the resulting price has been the single largest obstacle to scaling cultivated meat in particular.

Future Fields, founded in Edmonton in 2018, took a different route. Its EntoEngine platform engineers fruit flies to express the target protein, then harvests it from the insects. Flies reproduce rapidly, need very little input, and require none of the capital infrastructure a fermentation facility does. The company describes the approach as roughly thirty times faster than tank-based production and scalable with minimal additional investment, since scaling means raising more flies rather than commissioning more steel.

The environmental case has been independently examined rather than merely asserted. The company’s FGF2 growth factor received the ACT Environmental Impact Factor Label from My Green Lab, the first growth factor to do so, which represents third-party assessment of manufacturing impact rather than a self-reported figure.

Commercially the company has moved from validating the platform to selling into it, shipping protein products to more than 60 companies and opening a 6,000 square foot facility in downtown Edmonton to support custom protein production for clients working with more difficult cell lines. It raised roughly $11 million in 2025 to expand that work. As a piece of Alberta’s economy it is a useful counterweight to the assumption that the province’s technology story is entirely about compute and energy.

The scaling argument is the crux of the business and it is genuinely unusual. Conventional biomanufacturing scales by building larger bioreactors, which means capital expenditure, construction time, regulatory qualification and a step change in cost at each expansion. Scaling a fly-based platform means raising more flies, which is closer to a linear operating cost than a capital one. A company whose expansion path avoids commissioning steel has a structurally different risk profile from one whose does not.

Cultivated meat, the application that first drew attention to this approach, has had a difficult few years. Several companies have retrenched, timelines have extended, and the sector has discovered that regulatory approval and consumer acceptance move more slowly than the engineering. A supplier positioned across research, therapeutics and food applications is considerably better placed than one betting on a single downstream market, and shipping to more than 60 companies suggests a customer base broader than any one category.

The insect platform carries advantages that are easy to overlook. Fruit flies have been a workhorse of genetics for more than a century, so the tooling for modifying them is mature and very well understood. They are also complex organisms capable of the post-translational modifications that simpler expression systems such as bacteria handle poorly, which matters for proteins where correct folding determines whether the product works at all.

For Edmonton the company is evidence that the city’s research base can produce companies in categories nobody planned for. Nothing in Alberta’s industrial strategy called for a fly biotechnology company, and the fact that one emerged and found international customers says something useful about what a strong university and patient early funding actually produce.

Growth factor economics explain why this problem attracted anyone at all. These proteins have historically been priced in a range that makes sense for laboratory research quantities and becomes prohibitive at industrial volume, and for cultivated meat in particular the cost of growth media has been the single largest obstacle between laboratory demonstration and commercial production. An order-of-magnitude reduction in that cost does not improve the industry’s margins so much as determine whether the industry exists.

The regulatory position varies sharply by application and shapes the commercial sequence. Selling growth factors for laboratory research carries a light burden. Supplying inputs to therapeutic manufacturing means operating under pharmaceutical quality systems with full traceability. Food applications bring another framework again. A platform company can address all three, but each requires its own quality infrastructure, and building them in the right order is a strategic question as much as a technical one.

Third-party environmental verification is more significant than it might appear in a sector prone to unsubstantiated claims. Biomanufacturing has a substantial footprint through energy for sterilisation and temperature control, water use and single-use plastics, and almost every company in the field asserts an improvement. Having an assessment conducted by an outside body converts a marketing claim into a procurement input, which matters to buyers with their own reporting obligations to satisfy.

The custom production service is the strategically interesting move. Manufacturing a catalogue of standard proteins is a product business competing on price. Producing proteins that clients cannot readily obtain elsewhere, including work in difficult cell lines such as neurons, is a capability business competing on what is possible. The second commands better margins, builds deeper customer relationships, and generates exactly the kind of hard problems that improve a platform.

All startups →Latest news →